(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 December 2014 (18.12.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/199316 A1

(51) International Patent Classification:
A61K 9/20 (2006.01) *A61K 31/4439* (2006.01)

(21) International Application Number:
PCT/IB2014/062136

(22) International Filing Date:
11 June 2014 (11.06.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/834,104 12 June 2013 (12.06.2013) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(71) Applicants *(for US only)*: **GALLI, Bruno** [CH/CH]; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **THOMA, Hubert** [DE/CH]; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **GRANDEURY, Arnaud** [FR/CH]; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **SPICKERMANN, Dirk** [DE/CH]; c/o Novartis Pharma Stein, Postfach, CH-4332 Stein (CH). **PUTZBACH, Karsten** [DE/CH]; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **MOLL, Klaus-Peter** [DE/CH]; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **UFER, Mike** [DE/CH]; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **GLANTZMANN, Jean-Marie** [FR/CH]; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **MUELLER-ZSIGMONDY, Martin** [DE/CH]; c/o Novartis Pharma AG, Postfach, CH-4002 Basel (CH).

(74) Agent: **ROUQUAYROL, Céline**; c/o Novartis Pharma AG, Patent Department, Forum 1, Novartis Campus, CH-4056 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title**: MODIFIED RELEASE FORMULATION

(57) **Abstract**: Drug products in the form of modified release formulations comprising the drug substance (-)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are 5 provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia.

WO 2014/199316 A1